UNITED STATES OF AMERICA et al v. JOHNSON & JOHNSON et al

  1. August 13, 2024

    Janssen Wants New FCA Trial As Relators Seek $1.85B Win

    Janssen has urged a New Jersey federal judge to toss a jury's $150 million False Claims Act verdict that found the pharmaceutical company illegally profited from the off-label marketing of popular HIV medications, while whistleblowers have asked the court for a whopping $1.85 billion judgment consisting of trebled damages and statutory penalties.

  2. June 14, 2024

    Janssen Hit With $150M Verdict In HIV Drug False Claims Suit

    A New Jersey federal jury hit Janssen with a $150 million False Claims Act verdict in a 12-year-old whistleblower suit, finding that the drugmaker violated the federal law as well as 27 related state FCA statutes by illegally profiting from the off-label marketing of two popular Janssen HIV medications.

  3. December 21, 2021

    Janssen Denied Early Defeat Of HIV Medication FCA Suit

    A New Jersey federal judge denied drugmaker Janssen Products LP's bid to beat a 9-year-old False Claims Act suit without a trial, ruling Tuesday that there are still many open questions in the suit over whether Janssen benefited from off-label marketing of two medications that can stave off HIV.

  4. April 08, 2019

    Janssen Needn't Show Earnings In Off-Label Use Suit

    Drugmaker Janssen Products LP doesn't have to turn over documents that show the profits it made by allegedly selling HIV/AIDS medication for off-label uses in violation of federal law, a New Jersey federal court ruled Monday.

  5. May 31, 2017

    Janssen Can't Escape Bulk Of FCA Suit Over HIV Drug

    A New Jersey federal judge ruled Wednesday that Janssen Products LP must face the bulk of claims in a False Claims Act lawsuit alleging the drugmaker unlawfully benefited from promoting off-label uses of HIV/AIDS medication, but said Johnson & Johnson couldn't be held liable simply because it's Janssen's corporate parent.